Overall rank by patents
#25,026
of 49,997 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 17 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).
The verdict
According to USPTO PatentsView, Procemex ranks #25,026 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 17 technology areas.
USPTO PatentsView assignee plate
Corpus R25026 · Foreign Corporation #25,026 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: PrimeVax Immuno-Oncology (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Procemex Oy · this assignee
33 score
3D Lighting… · lowest
7 score
What this shows Procemex's Innovation Score is 33.5/100 (45th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Procemex Oy is a focused PatentsView assignee: 17 CPC subclasses with 90.9% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2016. By volume, Procemex sits between PrimeVax Immuno-Oncology and Propex Operating Company, LLC.
Procemex Oy shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PrimeVax Immuno-Oncology
11 patents
PrinterLogic, Inc.
11 patents
Privacy4Cars, Inc.
11 patents
Pro-Tech Manufacturing and Distribution, Inc.
11 patents
Proctor Consulting, LLC
11 patents
Profire Energy, Inc.
11 patents
Progressive Sterilization, LLC
11 patents
Propex Operating Company, LLC
11 patents
Procemex Oy
11 patents
What this shows Procemex holds 11 patents at rank #25,018, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #25,018 in granted patent volume.
Other assignees with the most granted patents in Procemex's primary technology class.
Procemex's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 45th percentile higher than 45% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 9.1% |
| 2019 | 1 | 9.1% |
| 2020 | 2 | 18.2% |
| 2021 | 3 | 27.3% |
| 2022 | 2 | 18.2% |
| 2024 | 1 | 9.1% |
| 2025partial year | 1 | 9.1% |
Top 15 of 17 technology areas
Overall rank by patents
#25,026
of 49,997 tracked assignees
33.5 out of 100
What to do with this data
Procemex Oy's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.